PRQRProQR Therapeutics N.V.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $1.86 · now $1.86 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, PRQR has typically landed between $1.30 and $2.63 — a range of −29.9% to +41.2% from the issuance price $1.86.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,990 overlapping 1 month windows · 2014-09-182026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($1.86) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where PRQR has typically landed a month from the 2026-09-16 close of $1.86 — the range is history, not a prediction.

$1.3worst · -29.9%$2.63best · +41.2%
  • now $1.86 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.83 (-1.4%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.59$2.08
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.3$2.63
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,990 windows spanning 2014-09-18 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2022-02-01−84.5%−84.5%+1.9%
2022-02-09−84.1%−84.6%+0.0%
2022-02-10−83.5%−84.0%+0.0%
3 best
2022-11-29+210.9%+0.0%+210.9%
2018-08-09+193.9%+0.0%+193.9%
2018-08-15+182.4%−3.9%+182.4%

2,990 overlapping windows · 2014-09-182026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
17%
−14.6%
n=12
Feb
42%
−8.6%
n=12
Mar
58%
−0.1%
n=12
Apr
33%
−2.1%
n=12
May
50%
+2.3%
n=12
Jun
58%
+4.5%
n=12
Jul
42%
−3.2%
n=12
Aug
83%
+9.8%
n=12
Sep
25%
+5.5%
n=12
Oct
33%
+3.9%
n=12
Nov
58%
+4.1%
n=12
Dec
58%
+20.2%
n=12

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$12026-07-31: 1 insider purchase, $354K — de Boer Daniel Anton2026-07-17: 1 insider purchase, $258K — Filius Bart2026-07-09: 1 insider purchase, $261K — de Boer Daniel Anton2026-07-07: 1 insider purchase, $239K — de Boer Daniel Anton2026-06-26: 1 insider purchase, $231K — Filius Bart2026-06: 1 open-market purchase, $231K2026-07: 4 open-market purchases, $1.1M↑ buys↓ salesdirector de Boer Daniel Anton — Purchase on 2026-07-31, filed 3 days after the tradedirector Filius Bart — Purchase on 2026-07-17, filed 4 days after the tradedirector de Boer Daniel Anton — Purchase on 2026-07-09, filed 4 days after the tradedirector de Boer Daniel Anton — Purchase on 2026-07-07, filed 1 day after the tradedirector Filius Bart — Purchase on 2026-06-26, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-31de Boer Daniel AntondirectorPurchase200,000 @ $1.77$354K+66.7% of holding+21.2%not yet — horizon still open500,000Form 4 · filed 3 days after the trade
2026-07-17Filius BartdirectorPurchase150,000 @ $1.72$258K+100.0% of holding+9.6%not yet — horizon still open300,000Form 4 · filed 4 days after the trade
2026-07-09de Boer Daniel AntondirectorPurchase150,000 @ $1.74$261K+100.0% of holding+4.0%not yet — horizon still open300,000Form 4 · filed 4 days after the trade
2026-07-07de Boer Daniel AntondirectorPurchase150,000 @ $1.59$239Kownership Δ n/a+15.7%not yet — horizon still open150,000Form 4 · filed 1 day after the trade
2026-06-26Filius BartdirectorPurchase150,000 @ $1.54$231Kownership Δ n/a+13.4%not yet — horizon still open150,000Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

1 award / exercise / gift record — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-02Hinsch Gylvin LykkedirectorAward / grant14,49514,495Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.